ArticleClinical lymphoma, myeloma & leukemia2015
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Article in Clinical lymphoma, myeloma & leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Allogeneic transplantation for plasma cell myeloma clears pre-transplant clonal haematopoiesis and is associated with a low rate of myeloid neoplasm post-cytotoxic-therapy.Bone marrow transplantation · 2026Article
- Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome.Frontiers in immunology · 2025Article
- Second Primary Malignancy in Ixazomib Maintenance Therapy for Multiple Myeloma: Case Report and Literature Review.Case reports in hematology · 2025Article
- Characteristics and outcomes of patients with lymphoma who developed therapy-related acute myeloid leukemia or myelodysplastic syndrome - a retrospective analysis of the Polish Adult Leukemia Group.Contemporary oncology (Poznan, Poland) · 2024Article
- The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw.Cancers · 2023Review
- Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.BMJ case reports · 2022Article
- Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.Annals of hematology · 2022Article
- Review
- Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma.Blood cancer journal · 2021Article
- Second primary malignancies in multiple myeloma: A review.Blood reviews · 2021Review
- Occurrence of a Clonal T-Cell Population in a Case of Chronic Myelomonocytic Leukemia.Clinical medicine insights. Blood disorders · 2021Article
- Targeting NF-κB Signaling for Multiple Myeloma.Cancers · 2020Review
- Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020Review
- Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.Haematologica · 2019Review
- Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma.Journal of clinical and experimental hematopathology : JCEH · 2018Article
- Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.Leukemia · 2018Article
- The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.Blood advances · 2017Article
- Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.Cancer medicine · 2017Article
- Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.Haematologica · 2016Article
- [Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundPatients with multiple myeloma (MM) have had significant improvements in outcomes. An increased risk of therapy-related myeloid neoplasms (t-MNs) has also developed. Little is known about the characteristics and outcomes of these patients. PATIENTS AND
methodsPatients with MM treated at our institution from 1993 to 2011 were reviewed. Forty-seven patients were diagnosed with t-MN. Our primary objective was to evaluate the interval to t-MN, response to treatment, and overall survival (OS).
resultsThe median patient age at the MM diagnosis was 65 years. Of the 47 patients, 32 (68.0%) initially received conventional chemotherapeutic agents, 7 (14.9%), novel agents (eg, lenalidomide, thalidomide, bortezomib), and 8 (17.0%), a combination. Twenty patients (42.6%) underwent high-dose chemotherapy and autologous hematopoietic stem cell transplantation. The median interval from the MM diagnosis to t-MN was 7 years (95% CI, 5.0-28.0). Of the 47 patients, 33 (70.2%) developed therapy-related myelodysplastic syndrome (t-MDS), 11 (23.4%) acute myeloid leukemia (t-AML), and 3 (6.4%) chronic myelomonocytic leukemia (t-CMML). The median age at the t-MN diagnosis was 65 years. Of the 47 patients, 26 (78.8%) with t-MDS, 9 (81.8%) with t-AML, and 1 (33.3%) with t-CMML had complex/high-risk cytogenetics. The median OS for all 47 patients after the t-MN diagnosis was 6.3 months (95% CI, 4.0-8.7).
conclusionThe development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.